Literature DB >> 15809287

Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration.

Carina Porporatto1, Ismael D Bianco, Silvia G Correa.   

Abstract

Chitosan is a cationic polysaccharide derived from the partial deacetylation of chitin, which exhibits particular properties: interacts with negatively charged sites on the cell surface; changes the permeability of intestinal epithelium, enhancing the uptake of peptides and proteins; and activates leukocytes. Antigens coadministered or encapsulated with the polysaccharide show improved mucosal and systemic humoral immune responses, although the mechanism is poorly understood. Herein, we characterized in Peyer's patches mesenteric lymph nodes and spleen molecular events triggered after oral administration of chitosan in the absence of protein antigen. Sixteen hours after feeding, we studied the uptake and distribution of the polysaccharide, the phenotype of recruited antigen-presenting cells (APC), the induction of cytokines such as tumor necrosis factor alpha, interleukin (IL)-12, IL-4, IL-10, and transforming growth factor-beta (TGF-beta), and the activation of T lymphocytes. We show here that the uptake of chitosan at inductive mucosal sites involves CD11b/c+ APC and that chitosan feeding increases the percentage of OX62+ dendritic cells, which up-regulate the major histocompatibility complex class II antigens without changing the expression of costimulatory CD80 or CD86 molecules. The polysaccharide elicits the release of IL-10 as well as the expression of IL-4 and TGF-beta in mucosa, and in spleen, the activation of CD3+ T cells occurs. Our results demonstrate that chitosan acts by enhancing the T helper cell type 2 (Th2)/Th3 microenvironment in the mucosa. A single dose of this polysaccharide exhibits local and systemic effects, and its activity could be relevant in the maintenance of the intestinal homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809287     DOI: 10.1189/jlb.0904541

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  25 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

2.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 3.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

4.  From secretome analysis to immunology: chitosan induces major alterations in the activation of dendritic cells via a TLR4-dependent mechanism.

Authors:  Christian Villiers; Mireille Chevallet; Hélène Diemer; Rachel Couderc; Heidi Freitas; Alain Van Dorsselaer; Patrice N Marche; Thierry Rabilloud
Journal:  Mol Cell Proteomics       Date:  2009-03-11       Impact factor: 5.911

5.  Ability of the polysaccharide chitosan to inhibit proliferation of CD4+ lymphocytes from mucosal inductive sites, in vitro and in vivo.

Authors:  C Porporatto; M M Canali; I D Bianco; S G Correa
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

6.  Conjugation of chitosan oligosaccharides via a carrier protein markedly improves immunogenicity of porcine circovirus vaccine.

Authors:  Guiqiang Zhang; Peiyuan Jia; Hongtao Liu; Tao Hu; Yuguang Du
Journal:  Glycoconj J       Date:  2018-07-26       Impact factor: 2.916

7.  The biocompatible polysaccharide chitosan enhances the oral tolerance to type II collagen.

Authors:  C Porporatto; M M Canali; I D Bianco; S G Correa
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

8.  Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs.

Authors:  Jaehyung Park; Renuka Ramanathan; Linhchi Pham; Kim A Woodrow
Journal:  Nanomedicine       Date:  2017-04-20       Impact factor: 5.307

9.  Glycated chitosan as a new non-toxic immunological stimulant.

Authors:  Sheng Song; Feifan Zhou; Robert E Nordquist; Raoul Carubelli; Hong Liu; Wei R Chen
Journal:  Immunopharmacol Immunotoxicol       Date:  2009-06       Impact factor: 2.730

10.  Anticoccidial activities of Chitosan on Eimeria papillata-infected mice.

Authors:  Mahmoud Abdel-Latif; Heba M Abdel-Haleem; Abdel-Azeem S Abdel-Baki
Journal:  Parasitol Res       Date:  2016-04-04       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.